Literature DB >> 15257543

Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability.

Friedrich Prall1, Thomas Dührkop, Volker Weirich, Christiane Ostwald, Peter Lenz, Horst Nizze, Malte Barten.   

Abstract

Previous studies have identified high numbers of intraepithelial T lymphocytes to be associated with good prognosis in various types of cancer. Few studies addressing this issue have been published for colorectal cancer. In a simulated prospective approach ("phase II prognostic factor study"), all nonmetachronous International Union Against Cancer (UICC) stage III colorectal cancers that were accessioned in the years 1994 to 1999 were included in the study (152 cases). Follow-up information as to vital status and occurrence of metachronous metastases could be obtained for all patients in the years 2001 and 2002. CD8+ intratumoral lymphocytes were quantified after immunostaining and referred to tumor cell area (CD8+ densities). Microsatellite status was determined by using the Bethesda panel of microsatellite markers. CD8+ densities ranged from 0 per square millimeter to 1436 per square millimeter of tumor area in a nonnormal distribution that was skewed toward low values. Univariate survival analyses revealed the 66th percentile as a stringent cutoff (CD8+high versus CD8+low), with CD8+high cases taking a significantly better clinical course. This prognostic impact appeared even more pronounced in the subset of patients with colon carcinomas who were receiving 5-fluouracil/leucovorin as adjuvant treatment (79 patients). Seventeen patients had carcinomas with high microsatellite instability (MSI-H). MSI-H-CD8+high cases (n = 11) showed an excellent prognosis, with tumor-free survival for 9 of the 11 patients. The prognostic effect of CD8+high was retained in Cox regression analyses when including UICC substages (IIIA to IIIC). Our results identify CD8+ tumor-infiltrating lymphocytes as a promising candidate for further evaluation in the ongoing search for prognostic and predictive factors of colorectal cancer, particularly if combined with microsatellite status.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15257543     DOI: 10.1016/j.humpath.2004.01.022

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  99 in total

Review 1.  Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.

Authors:  Katsuhiko Nosho; Yoshifumi Baba; Noriko Tanaka; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Edward Giovannucci; Glenn Dranoff; Charles S Fuchs; Shuji Ogino
Journal:  J Pathol       Date:  2010-12       Impact factor: 7.996

2.  Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ.

Authors:  Moritz Koch; Philipp Beckhove; Jan Op den Winkel; Daniel Autenrieth; Philipp Wagner; Daniel Nummer; Sebastian Specht; Dalibor Antolovic; Luis Galindo; Friedrich H Schmitz-Winnenthal; Volker Schirrmacher; Markus W Büchler; Jürgen Weitz
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

3.  Lymph node yield after colectomy for cancer: is absence of mismatch repair a factor?

Authors:  Tushar Samdani; Molly Schultheis; Zsofia Stadler; Jinru Shia; Tiffany Fancher; Justine Misholy; Martin R Weiser; Garrett M Nash
Journal:  Dis Colon Rectum       Date:  2015-03       Impact factor: 4.585

4.  Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.

Authors:  Kaoru Nagato; Shinichiro Motohashi; Fumihiro Ishibashi; Kohsuke Okita; Kazuki Yamasaki; Yasumitsu Moriya; Hidehisa Hoshino; Shigetoshi Yoshida; Hideki Hanaoka; Shin-Ichiro Fujii; Masaru Taniguchi; Ichiro Yoshino; Toshinori Nakayama
Journal:  J Clin Immunol       Date:  2012-04-26       Impact factor: 8.317

5.  Expression analysis and association of RBBP6 with apoptosis in colon cancers.

Authors:  Zodwa Dlamini; Charleen Rupnarain; Sarala Naicker; Rodney Hull; Zukile Mbita
Journal:  J Mol Histol       Date:  2016-02-23       Impact factor: 2.611

Review 6.  Cancer immunology--analysis of host and tumor factors for personalized medicine.

Authors:  Shuji Ogino; Jérôme Galon; Charles S Fuchs; Glenn Dranoff
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

7.  Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

8.  Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer.

Authors:  Vanessa Deschoolmeester; Marc Baay; Wim Wuyts; Eric Van Marck; Paul Pelckmans; Filip Lardon; Jan B Vermorken
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

9.  Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.

Authors:  Vanessa Deschoolmeester; Marc Baay; Eric Van Marck; Joost Weyler; Peter Vermeulen; Filip Lardon; Jan B Vermorken
Journal:  BMC Immunol       Date:  2010-04-12       Impact factor: 3.615

10.  Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.

Authors:  Yi-Lan Zhang; Jiang Li; Hao-Yuan Mo; Fang Qiu; Li-Min Zheng; Chao-Nan Qian; Yi-Xin Zeng
Journal:  Mol Cancer       Date:  2010-01-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.